SPL 028
Alternative Names: SPL-028Latest Information Update: 16 Feb 2024
At a glance
- Originator Small Pharma
- Developer Cybin
- Class Antidepressants; Dimethylamines; Neuropsychotherapeutics; Organic deuterium compounds; Small molecules; Tryptamines
- Mechanism of Action Serotonin 5-HT2A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Depressive disorders
Most Recent Events
- 14 Feb 2024 Cybin has patent protection for formulations of certain deuterated analogs of deuterated dimethyltryptamine in Canada
- 07 Feb 2024 Cybin has patent protection for DMT and dDMT compounds in Japan
- 08 Jan 2024 Pharmacokinetics, efficacy and adverse events data from a phase I trial in Depressive disorders released by Cybin